Cholangiocarcinoma (CCA) is a highly lethal adenocarcinoma of the hepatobiliary system,
which can be classified as intrahepatic, perihilar and distal. Each anatomic subtype has …

Due to the advantages in efficacy and safety compared with traditional chemotherapy drugs,
targeted therapeutic drugs have become mainstream cancer treatments. Since the first …

Background Alterations in fibroblast growth factor receptor 2 (FGFR2) have emerged as
promising drug targets for intrahepatic cholangiocarcinoma, a rare cancer with a poor …

The heterogeneity of the tumour immune microenvironment (TIME), organized by various
immune and stromal cells, is a major contributing factor of tumour metastasis, relapse and …

Background Treatment options are sparse for patients with advanced cholangiocarcinoma
after progression on first-line gemcitabine-based therapy. FGFR2 fusions or rearrangements …

We performed proteogenomic characterization of intrahepatic cholangiocarcinoma (iCCA)
using paired tumor and adjacent liver tissues from 262 patients. Integrated proteogenomic …

Cholangiocarcinoma (CCA) includes a cluster of highly heterogeneous biliary malignant
tumours that can arise at any point of the biliary tree. Their incidence is increasing globally …

Lipids are a complex and diverse group of molecules with crucial roles in many
physiological processes, as well as in the onset, progression, and maintenance of cancers …

Background Fibroblast growth factor receptor (FGFR) 2 gene alterations are involved in the
pathogenesis of cholangiocarcinoma. Pemigatinib is a selective, potent, oral inhibitor of …

Histomorphology has been a mainstay of cancer diagnosis in anatomic pathology for many
years. DNA methylation profiling is an additional emerging tool that will serve as an adjunct …